## PATENT ASSIGNMENT

# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
Merck & Co., Inc.	06/26/2009
Rosetta Inpharmatics LLC	06/26/2009

#### **RECEIVING PARTY DATA**

Name:	Microsoft Corporation	
Street Address:	One Microsoft Way	
City:	Redmond	
State/Country:	WASHINGTON	
Postal Code:	98052	

#### PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	6801859

## **CORRESPONDENCE DATA**

Fax Number: (503)595-5301

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 503-595-5300

Email: kristina.bushey@klarquist.com

Correspondent Name: Gregory L. Maurer

Address Line 1: 121 S.W. Salmon Street, Suite 1600

Address Line 2: One World Trade Center
Address Line 4: Portland, OREGON 97204

ATTORNEY DOCKET NUMBER: 3382-84128-01

NAME OF SUBMITTER: Gregory L. Maurer

**Total Attachments: 8** 

source=Rosetta Assignment#page1.tif source=Rosetta Assignment#page2.tif

PATENT 501052721 REEL: 023708 FRAME: 0345

OF \$40.00 6801859

source=Rosetta Assignment#page3.tif source=Rosetta Assignment#page4.tif source=Rosetta Assignment#page5.tif source=Rosetta Assignment#page6.tif source=Rosetta Assignment#page7.tif source=Rosetta Assignment#page8.tif

#### ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS (this "Assignment of Patents") is executed and delivered as of June 26, 2009, by Merck & Co., Inc., a New Jersey corporation ("Merck"), and Rosetta Inpharmatics LLC, a Delaware limited liability company and wholly owned subsidiary of Merck (the "Company" and together with Merck, "Assignors"), in favor of Microsoft Corporation, a Washington corporation ("Assignee"), pursuant to that certain Asset Purchase Agreement dated as of June 1, 2009 (the "Purchase Agreement"), between Assignors and Assignee. Capitalized terms not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement.

WHEREAS, Assignors are the owners of the patents and/or patent applications listed on Schedule I which is attached hereto and incorporated by this reference (collectively, the "Patents"); and

WHEREAS, pursuant to the Purchase Agreement, Assignors have agreed to transfer, and Assignee has agreed to accept, all of the Patents; and

WHEREAS, the purpose of this document is to confirm, complete and memorialize such transfer of the Patents from Assignors to Assignee;

NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged:

Assignors hereby sells, assigns, transfers and sets over unto Assignee, its successors, legal representatives and assigns, Assignors' entire right, title and interest in, to and under the Patents and all applications claiming priority thereto under 35 U.S.C. §119(e) and divisions, renewals and continuations thereof, and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which have been and may hereafter be filed for said Patents in any country or countries foreign to the United States, including but not limited to those foreign patents and applications specifically described in Schedule 1, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof.

Assignors authorize and request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

Assignors, at Assignee's expense, agree to execute and deliver at the request of the Assignee, all papers, instruments, and assignments, and to perform any other reasonable acts the Assignee may require in order to vest all Assignors' rights, title, and interest in and to the Patents in the Assignee and/or to provide evidence to support any of the foregoing in the event such evidence is deemed necessary by the Assignee, to the extent such evidence is in the possession or control of Assignors.

Nothing contained in this Assignment of Patents shall expand, reduce, modify or waive any rights or obligations of the parties under the Purchase Agreement. In the event that any of the provisions of this Assignment of Patents are determined to conflict with the terms of the Purchase Agreement, the terms of the Purchase Agreement shall control.

[Signatures are on the following page]

## SIGNATURE PAGE —ASSIGNMENT OF PATENTS

IN WITNESS WHEREOF, the Assignors have caused this Assignment of Patents to be executed as of the date first written above.

	ASSIGNORS:
e e	MERCK & CO., INC.  By:  Name: Felex Kim  Its: Executive Vice Presidenta Resident  Menck Research Labs
	ROSETTA INPHARMATICS LLC  By: Name: Rupert Vessey  Its: Senior Vice President  Rosetta Enpharmatics LLC
COUNTERSIGNATURE	
The Assignee has caused this As	signment of Patents to be executed on the date

# The Assignee has caused this Assignment of Patents to be executed on the date

shown below.

MICROSOFT CORPORATION Name: D. BARTLEY EPPENAMER Title: ChiEF PATENT Date: 12/4/09

**ASSIGNEE:** 

STATE OF	Lew servey
COUNTY OF_	Longroez"

On this day of day of 2009, before me, a Notary Public in and for said State, personally appeared Peter or Ropert Vessey personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose names(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS, my hand and official seal.

Notary Public

PALLA A DEPLICATE
METANY PUBLIC - STATE OF MEN JENSEY
MY COMMISSION DEPLICAMARCH 12 2011

PATENT

**REEL: 023708 FRAME: 0350** 

# SCHEDULE 1 to the ASSIGNMENT OF PATENTS

		Issued Patent or			
		Patent Application	Date	Date	
	Title	##	Filed	Issued	Inventor(s)
		Issued U.S.	Patents		
1	Methods for Identifying	5,965,352	5/8/1998	10/12/1999	Friend &
	Pathways of Drug Action				Stoughton
2	Methods for Testing	6,132,969	6/19/1998	10/17/2000	Stoughton &
	Biological Network Models				Кагр
3	Method for Determining	6,146,830	9/23/1998	11/14/2000	Friend &
	the Presence of a Number				Stoughton
	of Primary Targets of a				
	Drug			0/00/000/	
4	Methods for Using Co-	6,203,987	10/27/1998	3/20/2001	Stoughton &
	Regulated Genesets to				Friend
	Enhance Detection &				
	Classification of Gene				
5	Expression Patterns Methods of Monitoring	6,218,122	6/16/1999	4/17/2001	Friend &
၂၁	Disease States &	0,210,122	0/10/1999	4/11/2001	Stoughton
	Therapies Using Gene				U.Jugiitori
	Expression Profiles				
6	Methods for Determining	6,222,093	12/28/1998	4/24/2001	Stoughton &
	Therapeutic Index from	-,			Marton
	Gene Expression Profiles				
7	Computer System &	6,300,078	10/20/2000	10/9/2001	Friend &
	Method for Determining a		-		Stoughton
	Number of Primary		**************************************		
L	Targets of a Drug				
8	Methods for Comparing a	6,303,291	10/20/2000	10/16/2001	Friend &
	Number of Primary			The second secon	Stoughton
	Targets for Two or More				
<u> </u>	Drug Compositions	6 004 470	4/20/4000	44/07/0004	Friend &
9	Methods of Determining	6,324,479	4/30/1999	11/27/2001	
	Protein Activity Levels		The state of the s	- Annie	Stoughton
	Using Gene Expression Profiles		1,000	Semidant of the Control of the Contr	
10	Statistical Combining of	6,351,712	12/28/1998	2/26/2002	Stoughton &
"	Cell Expression Profiles	5,551,712	1414011000		Dai
11	Methods for Drug	6,370,478	12/28/1998	4/9/2002	Stoughton &
' '	Interaction Prediction				Stepaniants
	Using Biological		***	mh cruseaurs	
	Response Profiles	:	-		
12	Method & System for	6,453,241	12/23/1998	9/17/2002	Bassett,
	Analyzing Biological			Trase 17 and 19	Buskirk,
	Response Signal Data				Bondarenko
13	Methods for Using Co-	6,468,476	10/27/1999	10/22/2002	Stoughton,
	Regulated Genesets to		Control	Accession	Friend, He
	Enhance Detection &		-	nagy given	
}	Classification of Gene		***************************************	Photocome.	Garage Control of the
Ĺ	Expression Patterns	<u> </u>			

		T 2221212	T ====================================		1
14	Methods for Generating	6,691,042	7/2/2001	2/10/2004	Weng & Dai
	Differential Profiles by Combining Data Obtained				****
	in Separate				
	Measurements				***************************************
15	Methods of Characterizing	6,801,859	12/23/1998	10/5/2004	Stoughton,
	Drug Activities Using	.,,			Friend, He
	Consensus Profiles	-44***********************************			
16	Method & System for	6,839,635	6/28/2002	1/4/2005	Bassett,
	Analyzing Biological				Buskirk,
	Response Signal Data		Tapakana a		Bondarenko
17	Method & System for	6,847,897	12/22/1999	1/25/2005	Bassett &
	Analyzing Biological	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		172072000	Bondarenko
	Response Signal Data		Annual Control of the		
18	Computer Systems for	6,859,735	8/13/1999	2/22/2005	Friend &
	Identifying Pathways of		· ·		Stoughton
19	Drug Action	6.050.750	40/00/4000	0/07/200r	0
19	Methods for Removing Artifact from Biological	6,950,752	12/23/1998	9/27/2005	Stoughton,
	Profiles				Friend, He
20	Methods of Diagnosing	6,973,388	2/14/2001	12/6/2005	Friend &
	Disease States Using	0,010,000		12/0/2000	Stoughton
	Gene Expression Profiles				J
21	Computer Systems and	7,130,746	10/12/2001	10/31/2006	Friend &
	Computer Programs for				Stoughton
	Determining Protein				ļ
	Activity Levels Using Gene Expression Profiles				
22	Methods of Determining	7,254,487	4/2/2001	8/7/2007	Marton &
	Therapeutic Index from	1,20 1, 101	.,,	0.1.2001	Stoughton
	Gene Expression Profiles				G to ag, no.
23	Computer Systems &	7,269,517	4/18/2003	9/11/2007	Bondarenko
	Methods for Analyzing				, many
	Experiment Design				
24	Methods for Analysis of	7,418,351	1/30/2003	8/26/2008	Weng
	Measurement Errors in Measured Signals				And the second s
	Measured Oighais				
		ding U.S. Pate		<b>9</b>	
1	Methods for Using Co-	10/273,489	10/18/2002		Friend,
	Regulated Genesets to				Stoughton, He
	Enhance Detection & Classification of Gene				
	Expression Patterns	Weight			
2	Examiner's amended	10/287,130	11/4/2002		Stoughton &
	title:Systems & Methods				Dai
	for Determining a				_ =
	Weighted Mean Intensity				
3	Methods & Compositions	10/332,305	9/24/2003		Stoughton &
e via	for Determining Gene	to III appropried	·		Hughes
	Function	· · · · · · · · · · · · · · · · · · ·		······································	

4	Improved Anova Method for Data Analysis	10/349,364	1/22/2003	Weng
5	Methods of Analyzing Multi-Channel Profiles	10/800,340	3/12/2004	Weng
6	Systems & Methods for Correcting Error in Biological Response Signal Data	11/042,653	1/24/2005	Stoughton & Dai
7	Statistical Combining of Cell Expression Profiles	11/042,654	1/24/2005	Stoughton & Dai
8	Systems and Methods for Evaluating the Significance of Differences in Biological Measurements	11/303,121	12/12/2005	Stoughton & Dai
9	Methods and Computer Systems For Analyzing High-Throughput Assays	11/440,195	5/23/2006	Weng, Dai, & Bartz
10	Discover Biological Features Using Composite Images	11/599,184	11/13/2006	Weng, Bondarenko, Vega, Henle, Hunt, Spiridonov
11	Methods for Determining Therapeutic Index from Gene Expression Profiles	11/879,161	7/16/2007	Marton, Stoughton
12	Computer Systems and Methods for Identifying Conserved Cellular Constituent Clusters Across Datasets	11/985,841	11/16/2007	Stepanìants, Lum, Kuraisa, Schadt
13	Regions of Interest Processing	61/107,988	10/23/2008	Hunt, Henle, Bondarenko
14	Peak Reassembly	12/313,222	11/17/2008	Henle & Hunt
15	LC/MS Centroid Processing	61/161,380	3/18/2009	Hunt & Henle
16	Non-Contiguous Regions Processing	12/421,562	4/9/2009	Henle & Hunt
17	Finding Paired Isotope Groups	PCT/US 08/065820	6/4/2008	Bondarenko, Spiridonov, Weng
18	Integrated Genomic System	PCT/US 08/078311	9/30/2008	Will & Anderson
19	Peak Reassembly	PCT/US 09/043671	5/12/2009	Henle & Hunt
20	Centroid Processing	61/219,293	6/22/2009	Hunt & Henle
	Issued and	Pending Fore	ign Patent Ap	
	Methods of Diagnosing Disease States Using Gene Expression Profiles	Australia 779902		Friend & Stoughton
	Methods of Diagnosing Disease States Using	Canada 2335299.00		Friend & Stoughton

Gene Expression Profiles		
Methods of Diagnosing Disease States Using Gene Expression Profiles	Japan 12-554833	Friend & Stoughton
Discover Biological Features Using Composite Images	Canada 2632188.00	Weng, Bondarenko, Vega, Henle, Hunt, Yates, Spiridonov
Discover Biological Features Using Composite Images	EPO 06837548.4	Weng, Bondarenko, Vega, Henle, Hunt, Yates, Spiridonov
Discover Biological Features Using Composite Images	Japan 2008-540277	Weng, Bondarenko, Vega, Henle, Hunt, Yates, Spiridonov

PATENT REEL: 023708 FRAME: 0354

**RECORDED: 12/29/2009**